|
T.TH
|
I hope it continues to keep working on your NETs and it improves your...
|
|
T.TH
|
The other odd thing about the Mary Crowley post is it is only for prostate...
|
|
T.TH
|
CanadaPiet you have to remember what the current standard of care benchmarks...
|
|
T.TH
|
This is a July 2022 article from a lab in China. I guess they're...
|
|
T.TH
|
Right - around 230,000 of the warrants have already been exercised and...
|
|
T.TH
|
It's on both. For Mary Crowley search under trials for the...
|
|
T.TH
|
Looks like the THTX use of MSLs is getting a bit of publicity. ...
|
|
T.TH
|
Speaking only for me, the point Biobob is that if you truly are invested like...
|
|
T.TH
|
Slowly, every day. For the length of time you've been complaining...
|
|
T.TH
|
So what are you exactly waiting for then? If you believe your own words, then...
|
|
T.TH
|
Once again showing the bright future for targeted cancer therapies in...
|
|
T.TH
|
Industry-wise, the NASH watchers are basically all looking at Madrigal who...
|
|
T.TH
|
I would say he did very well projecting confidence in what they are doing...
|
|
T.TH
|
I think that's Ed Nash, but I'm not 100% certain. He's...
|
|
T.TH
|
Yes - was slight delay but no info lost. Paul actually mentioned the...
|
|
T.TH
|
I have thought the same thing with the 8 lines. I suppose it is the fate of...
|
|
T.TH
|
Here's the interesting thing about the SORT1+ Platform. What they've...
|
|
T.TH
|
Agree, it's only useful on solid milestone results. Otherwise, no...
|
|
T.TH
|
I will be interested to see if it's Ed Nash or the Canaccord oncology...
|
|
T.TH
|
Helpful historical summary. As an old inv industry vet, I would say my...
|